Hydroxysafflor Yellow A Improves Motor Dysfunction in the Rotenone-Induced Mice Model of Parkinson's Disease

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2017 Jan 19

PMID 28097465

Citations 4

Authors

Tian Wang

Lijie Wang

Cuiting Li

Bing Han

Zhenhua Wang

Ji Li

Yan Lv

Shuyun Wang

Fenghua Fu

Affiliations

Soon will be listed here.

Abstract

Dopamine D3 receptor (DRD3) is diminished in patients of Parkinson's disease (PD). Brain-derived neurotrophic factor (BDNF) is responsible for regulating expression of the DRD3 in the brain. Our previous study showed that hydroxysafflor yellow A (HSYA) could increase BDNF content in the striatum of PD mice. This experiment aimed to evaluate whether HSYA can improve the motor dysfunction induced by rotenone through regulating the BDNF/TrkB/DRD3 signaling pathway in mice. Male C57/BL6 mice were intraperitoneally treated with HSYA. Thirty minutes later, they were intragastrically administered with rotenone at a dose of 30 mg/kg. Pole, rotarod and open field tests were investigated at 28 d. Then, tyrosine hydroxylase (TH) in substantia nigra was observed by immunohistochemistry. Dopamine content was detected by high-performance liquid chromatography. The expressions of BDNF, phospho-tropomyosin-related kinase B (p-TrkB), tropomyosin-related kinase B (TrkB), phospho-phosphoinositide 3-kinase (p-PI3K), phosphoinositide 3-kinase (PI3K), phospho-protein kinase B (p-AKT), protein kinase B (AKT), and DRD3 were assayed by western blotting. Behavioral tests showed that rotenone-challenged mice displayed motor dysfunction. However, treatment with HSYA improved motor dysfunction induced by rotenone. HSYA treatment increased not only the number of TH-containing dopaminergic neurons in substantia nigra, but also the dopamine content in the striatum in PD mice. Moreover, the expressions of BDNF, p-TrkB/TrkB, DRD3, p-PI3K/PI3K, p-AKT/AKT were significantly increased in rotenone plus HSYA group. Our results indicated that HSYA improved motor dysfunction in rotenone-induced PD model and the pharmacological action of HSYA was related to regulating BDNF/TrkB/DRD3 signaling pathway, at least, in part.

Citing Articles

Hydroxysafflor yellow A: a natural pigment with potential anticancer therapeutic effect.

Wang Y, An J, Zhou J, Chang L, Zhang Q, Peng F Front Pharmacol. 2025; 15:1495393.

PMID: 39877386 PMC: 11772350. DOI: 10.3389/fphar.2024.1495393.

Ellagic Acid Protects Dopamine Neurons via Inhibition of NLRP3 Inflammasome Activation in Microglia.

He X, Zhou Y, Sheng S, Li J, Wang G, Zhang F Oxid Med Cell Longev. 2020; 2020:2963540.

PMID: 33294118 PMC: 7690998. DOI: 10.1155/2020/2963540.

Protective effect of hydroxysafflor yellow A on dopaminergic neurons against 6-hydroxydopamine, activating anti-apoptotic and anti-neuroinflammatory pathways.

Yang X, Li Y, Chen L, Xu M, Wu J, Zhang P Pharm Biol. 2020; 58(1):686-694.

PMID: 32658590 PMC: 7470140. DOI: 10.1080/13880209.2020.1784237.

Icariin attenuates neuroinflammation and exerts dopamine neuroprotection via an Nrf2-dependent manner.

Zhang B, Wang G, He J, Yang Q, Li D, Li J J Neuroinflammation. 2019; 16(1):92.

PMID: 31010422 PMC: 6477740. DOI: 10.1186/s12974-019-1472-x.

Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases.

Ao H, Feng W, Peng C Evid Based Complement Alternat Med. 2018; 2018:8259280.

PMID: 30356354 PMC: 6176289. DOI: 10.1155/2018/8259280.

References

Yoshii A, Constantine-Paton M . Postsynaptic BDNF-TrkB signaling in synapse maturation, plasticity, and disease. Dev Neurobiol. 2010; 70(5):304-22. PMC: 2923204. DOI: 10.1002/dneu.20765. View

Sun L, Yang L, Xu Y, Liang H, Han J, Zhao R . Neuroprotection of hydroxysafflor yellow A in the transient focal ischemia: inhibition of protein oxidation/nitration, 12/15-lipoxygenase and blood-brain barrier disruption. Brain Res. 2012; 1473:227-35. DOI: 10.1016/j.brainres.2012.07.047. View

Razgado-Hernandez L, Espadas-Alvarez A, Reyna-Velazquez P, Sierra-Sanchez A, Anaya-Martinez V, Jimenez-Estrada I . The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson's disease. PLoS One. 2015; 10(2):e0117391. PMC: 4332861. DOI: 10.1371/journal.pone.0117391. View

Simms S, Huettner D, Kortagere S . In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. Neuropharmacology. 2015; 100:106-15. DOI: 10.1016/j.neuropharm.2015.04.004. View

Noelker C, Morel L, Osterloh A, Alvarez-Fischer D, Lescot T, Breloer M . Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease. J Neuroinflammation. 2014; 11:86. PMC: 4018945. DOI: 10.1186/1742-2094-11-86. View

Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T . Parkinsonian rotenone mouse model: reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull. 2011; 34(1):92-6. DOI: 10.1248/bpb.34.92. View

Kassel S, Schwed J, Stark H . Dopamine D3 receptor agonists as pharmacological tools. Eur Neuropsychopharmacol. 2014; 25(9):1480-99. DOI: 10.1016/j.euroneuro.2014.11.005. View

Guillin O, Diaz J, Carroll P, Griffon N, Schwartz J, Sokoloff P . BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001; 411(6833):86-9. DOI: 10.1038/35075076. View

Ren Y, Liu W, Jiang H, Jiang Q, Feng J . Selective vulnerability of dopaminergic neurons to microtubule depolymerization. J Biol Chem. 2005; 280(40):34105-12. DOI: 10.1074/jbc.M503483200. View

10.

Almeida R, Manadas B, Melo C, Gomes J, Mendes C, Graos M . Neuroprotection by BDNF against glutamate-induced apoptotic cell death is mediated by ERK and PI3-kinase pathways. Cell Death Differ. 2005; 12(10):1329-43. DOI: 10.1038/sj.cdd.4401662. View

11.

Yang Y, Qiu W, Hao Y, Lv Z, Jiao S, Teng J . The efficacy of traditional Chinese Medical Exercise for Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2015; 10(4):e0122469. PMC: 4382160. DOI: 10.1371/journal.pone.0122469. View

12.

Porritt M, Stanic D, Finkelstein D, Batchelor P, Lockhart S, Hughes A . Dopaminergic innervation of the human striatum in Parkinson's disease. Mov Disord. 2005; 20(7):810-8. DOI: 10.1002/mds.20399. View

13.

Wang T, Duan S, Wang S, Lu Y, Zhu Q, Wang L . Coadministration of hydroxysafflor yellow A with levodopa attenuates the dyskinesia. Physiol Behav. 2015; 147:193-7. DOI: 10.1016/j.physbeh.2015.04.038. View

14.

Carnicella S, Drui G, Boulet S, Carcenac C, Favier M, Duran T . Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatry. 2014; 4:e401. PMC: 4080324. DOI: 10.1038/tp.2014.43. View

15.

Heng Y, Zhang Q, Mu Z, Hu J, Yuan Y, Chen N . Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra. Toxicol Lett. 2016; 243:7-21. DOI: 10.1016/j.toxlet.2015.12.005. View

16.

Lin Z, Dodd C, Filipov N . Short-term atrazine exposure causes behavioral deficits and disrupts monoaminergic systems in male C57BL/6 mice. Neurotoxicol Teratol. 2013; 39:26-35. DOI: 10.1016/j.ntt.2013.06.002. View

17.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S . Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015; 14(8):855-866. PMC: 5217462. DOI: 10.1016/S1474-4422(15)00006-X. View

18.

Howells D, Porritt M, Wong J, Batchelor P, Kalnins R, Hughes A . Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000; 166(1):127-35. DOI: 10.1006/exnr.2000.7483. View

19.

Levesque D, Martres M, Diaz J, Griffon N, Lammers C, Sokoloff P . A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A. 1995; 92(5):1719-23. PMC: 42591. DOI: 10.1073/pnas.92.5.1719. View

20.

Beaulieu J, Espinoza S, Gainetdinov R . Dopamine receptors - IUPHAR Review 13. Br J Pharmacol. 2015; 172(1):1-23. PMC: 4280963. DOI: 10.1111/bph.12906. View